147 related articles for article (PubMed ID: 35318162)
41. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
Tanaka I; Tanaka Y; Soen S; Oshima H
J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
[TBL] [Abstract][Full Text] [Related]
43. The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report.
Yamamoto T; Taketsuna M; Guo X; Sato M; Sowa H
J Bone Miner Metab; 2014 Nov; 32(6):699-708. PubMed ID: 24368586
[TBL] [Abstract][Full Text] [Related]
44. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).
Soen S; Fujiwara S; Takayanagi R; Kajimoto K; Tsujimoto M; Kimura S; Sato M; Krege JH; Enomoto H
Curr Med Res Opin; 2017 Nov; 33(11):2049-2056. PubMed ID: 28699789
[TBL] [Abstract][Full Text] [Related]
45. [Treatment of osteoporosis with PTH].
Takeuchi Y
Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
[TBL] [Abstract][Full Text] [Related]
46. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
[TBL] [Abstract][Full Text] [Related]
47. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
48. Four-Year Teriparatide Followed by Denosumab
Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
[TBL] [Abstract][Full Text] [Related]
49. Teriparatide: a review.
Quattrocchi E; Kourlas H
Clin Ther; 2004 Jun; 26(6):841-54. PubMed ID: 15262455
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
Nasomyont N; Keefe C; Tian C; Hornung L; Khoury J; Tilden JC; Hochwalt P; Jackson E; Rybalsky I; Wong BL; Rutter MM
Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
[TBL] [Abstract][Full Text] [Related]
51. Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Chen LX; Zhou ZR; Li YL; Ning GZ; Zhang TS; Zhang D; Feng SQ
PLoS One; 2015; 10(5):e0128032. PubMed ID: 26010450
[TBL] [Abstract][Full Text] [Related]
52. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
54. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.
Ljunggren Ö; Barrett A; Stoykov I; Langdahl BL; Lems WF; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Karras D; Marin F
BMC Musculoskelet Disord; 2013 Aug; 14():251. PubMed ID: 23968239
[TBL] [Abstract][Full Text] [Related]
55. Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.
Zhao Y; Johnston SS; Smith DM; McMorrow D; Krohn K; Krege J
Osteoporos Int; 2013 Sep; 24(9):2525-33. PubMed ID: 23529293
[TBL] [Abstract][Full Text] [Related]
56. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
Leder BZ
Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
[TBL] [Abstract][Full Text] [Related]
57. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.
Bhandari M; Jin L; See K; Burge R; Gilchrist N; Witvrouw R; Krohn KD; Warner MR; Ahmad QI; Mitlak B
Clin Orthop Relat Res; 2016 May; 474(5):1234-44. PubMed ID: 26932738
[TBL] [Abstract][Full Text] [Related]
58. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
Cosman F; Peterson LR; Towler DA; Mitlak B; Wang Y; Cummings SR
J Clin Endocrinol Metab; 2020 Nov; 105(11):3384-95. PubMed ID: 32658264
[TBL] [Abstract][Full Text] [Related]
59. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
Sowa H; Hamaya E; Yamamoto T
Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
[TBL] [Abstract][Full Text] [Related]
60. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.
Burch J; Rice S; Yang H; Neilson A; Stirk L; Francis R; Holloway P; Selby P; Craig D
Health Technol Assess; 2014 Feb; 18(11):1-180. PubMed ID: 24534414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
